Showing 20 of 132 recruiting trials for “precursor-t-cell-acute-lymphoblastic-leukemia”
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
RecruitingNCT06334835 ↗
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
👨⚕️ Ryan D. Cassaday, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2023View details ↗
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
👨⚕️ Nelson Hamerschlak, MD, PhH, Hospital Israelita Albert Einstein📍 1 site📅 Started Feb 2023View details ↗
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Co-administration of CART22-65s and huCART19 for B-ALL
Pilot Imaging Study of Leukemia
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
👨⚕️ Janine Stutterheim, Dr, Princess Maxima Center for Pediatric Oncology in The Netherlands📍 112 sites📅 Started Dec 2022View details ↗
RecruitingNCT05929976 ↗
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
CAV Regimen for R/R Ph- B-ALL
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
Enrolling by InvitationNCT05509855 ↗
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
RecruitingNCT05334069 ↗
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingNCT05750706 ↗
Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
👨⚕️ Marianna Criscuolo, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Jun 2022View details ↗
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →